Thomas Mandl1,2, Tanja Schjødt Jørgensen3,4, Marie Skougaard1,2, Peter Olsson1,2, Lars-Erik Kristensen1,2. 1. From the Section of Rheumatology, Skåne University Hospital, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden; and the Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark. 2. T. Mandl, MD, PhD, Section of Rheumatology, Skåne University Hospital, Department of Clinical Sciences Malmö, Lund University; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; M. Skougaard, MB, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; P. Olsson, MD, Section of Rheumatology, Skåne University Hospital, Department of Clinical Sciences Malmö, Lund University; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. 3. From the Section of Rheumatology, Skåne University Hospital, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden; and the Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark. thomas.mandl@med.lu.se. 4. T. Mandl, MD, PhD, Section of Rheumatology, Skåne University Hospital, Department of Clinical Sciences Malmö, Lund University; T.S. Jørgensen, MSc, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; M. Skougaard, MB, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg; P. Olsson, MD, Section of Rheumatology, Skåne University Hospital, Department of Clinical Sciences Malmö, Lund University; L.E. Kristensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg. thomas.mandl@med.lu.se.
Abstract
OBJECTIVE: To study longterm work disability and possible predictors in newly diagnosed patients with primary Sjögren syndrome (pSS). METHODS: Because we wanted to include only patients with full work availability potential, eligible patients were aged 18-62 years. Fifty-one patients (mean age 46 yrs, range 18-61 yrs, 50 women) diagnosed with pSS between January 2001 and December 2012 were included in the study. For each patient we randomly selected 4 reference subjects from the general population and matched for age, sex, and area of residence. We linked data to the Swedish Social Insurance Agency and calculated the proportion as well as net days of work disability in 30-day intervals from 12 months before pSS diagnosis until 24 months after . RESULTS: Work disability was increased in patients with pSS in comparison to general population comparators. At diagnosis, 26% of patients were work-disabled, while 37% and 41% were disabled at 12 and 24 months after diagnosis, respectively (p < 0.05 and p < 0.05 vs baseline). Prior work disability status at diagnosis (OR 15.4, 95% CI 2.9-81.9; p = 0.001), concomitant fibromyalgia (OR 10.5, 95% CI 2.0-56.0; p = 0.006), and each additional year of age (OR 1.1, 95% CI 1.0-1.2; p = 0.009) were found to be associated with work disability 24 months after diagnosis. CONCLUSION: Patients with pSS showed an increased work disability, in comparison with the general population, which increased significantly during the first 2 years after diagnosis. Work disability at diagnosis, concomitant fibromyalgia, and increasing age, but not anti-SSA/anti-SSB antibodies or disease activity, were associated with longterm work disability.
OBJECTIVE: To study longterm work disability and possible predictors in newly diagnosed patients with primary Sjögren syndrome (pSS). METHODS: Because we wanted to include only patients with full work availability potential, eligible patients were aged 18-62 years. Fifty-one patients (mean age 46 yrs, range 18-61 yrs, 50 women) diagnosed with pSS between January 2001 and December 2012 were included in the study. For each patient we randomly selected 4 reference subjects from the general population and matched for age, sex, and area of residence. We linked data to the Swedish Social Insurance Agency and calculated the proportion as well as net days of work disability in 30-day intervals from 12 months before pSS diagnosis until 24 months after . RESULTS: Work disability was increased in patients with pSS in comparison to general population comparators. At diagnosis, 26% of patients were work-disabled, while 37% and 41% were disabled at 12 and 24 months after diagnosis, respectively (p < 0.05 and p < 0.05 vs baseline). Prior work disability status at diagnosis (OR 15.4, 95% CI 2.9-81.9; p = 0.001), concomitant fibromyalgia (OR 10.5, 95% CI 2.0-56.0; p = 0.006), and each additional year of age (OR 1.1, 95% CI 1.0-1.2; p = 0.009) were found to be associated with work disability 24 months after diagnosis. CONCLUSION:Patients with pSS showed an increased work disability, in comparison with the general population, which increased significantly during the first 2 years after diagnosis. Work disability at diagnosis, concomitant fibromyalgia, and increasing age, but not anti-SSA/anti-SSB antibodies or disease activity, were associated with longterm work disability.
Entities:
Keywords:
PRIMARY SJÖGREN SYNDROME; WORK DISABILITY